MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Indivior warns on profits as competitors launch generic opioid addiction treatment

StockMarketWire.com

Indivior warned Wednesday that net revenue and net income would fall short of previous guidance, as the launch of generic versions of its opioid addiction treatment in the United States would weigh on performance.

The profit warning came after Dr.Reddys Laboratories and U.S.-based Mylan NV received approval from the Food and Drug Administration in June to launch a generic version of Indiviors Suboxone Film.

The company previously guided for 2018 net revenue in the range of $1.13bn to $1.17bn and adjusted net income of $280m to $320m. Story provided by StockMarketWire.com